In contrast, no difference was found for mOS or OS, when AML patients were stratified according to the TF PCA level of intact PBMCs using either 735 AU/106 cells (corresponding to the 95th percentile of TF PCA levels within the control group) or 293 AU/106 cells (corresponding to the median TF PCA level within the patient cohort) as the cut-off value (Fig. 6c, d). This evidence concerns the gene TF and acute myeloid leukemia.